Cord Blood News Volume 7.00 | Jan 8 2015

Allogeneic Stem-Cell Transplantation in Patients with NPM1-Mutated Acute Myeloid Leukemia: Results from a Prospective Donor versus No-Donor Analysis of Patients after Upfront HLA Typing within the SAL-AML 2003 Trial
The authors assessed the predictive value with regard to allogeneic stem-cell transplantation (SCT), they compared the clinical course of patients with mutated nucleophosmin-1 (NPM1) gene acute myeloid leukemia (AML) eligible for allogeneic SCT in a donor versus no-donor analysis. [J Clin Oncol] Abstract

Optimal Method for Collection of Umbilical Cord Blood: An Egyptian Trial for a Public Cord Blood Bank
Investigators evaluated the effect of the method of collection of umbilical cord blood on the yield of the cord blood units. They found that in utero collection gave significantly larger volumes of cord blood and higher total nucleated cell counts than ex utero collection. [Transfusion] Abstract

Human Mesenchymal Stem Cells as a Novel Platform for Simultaneous Evaluation of Cytotoxicity and Genotoxicity of Pharmaceuticals
The authors grew umbilical cord mesenchymal stem cells (UC-MSCs) on coverslips eliminating the cumbersome technique involving hypotonic treatment, fixation and preparing smears required for suspension culture. They inspected the cytotoxic and genotoxic effects of two known mutagens, mitomycin-C and hydrogen peroxide, on UC-MSCs, lymphocytes and A549 cells. [Mutagenesis] Abstract

Use of Allogeneic Stem Cell Transplantation for Moderate-Severe Glanzmann Thrombasthenia
Researchers report the case of an eight-month-old girl diagnosed with moderate-severe Glanzmann thrombasthenia, who was successfully treated with a reduced-intensity, human leukocyte antigen-identical allogeneic stem cell transplantation. [Platelets] Abstract

Prevalence and Clinical Significance of Potential Drug-Drug Interaction in Hematopoietic Stem Cell Transplantation
Investigators performed a cross-sectional study based on the evaluation of prescriptions to hematopoietic stem cell transplantation patients on the day of infusion. The potential drug-drug interactions were analyzed using the DRUG-REAX^® system and classified according to the severity level, available scientific evidence, time of onset, and potential clinical impact. [Cancer Chemother Pharmacol] Abstract

Hematopoietic Stem Cell Transplantation for Treatment of Primary CNS Lymphoma: Single Center Experience and Literature Review
Researchers report our single center experience with five primary central nervous system (CNS) lymphoma patients, who had achieved an objective response after a high-dose methotrexate based induction therapy and consecutively received a high-dose chemotherapy, consisting of carmustine and thiotepa, followed by autologous hematopoietic stem cell transplantation. [Eur J Haematol] Abstract

Patterns of Monocyte Subpopulations and Their Surface Expression of HLA-DR during Adverse Events after Hematopoietic Stem Cell Transplantation
Scientists describe the monocyte subpopulations and their human leukocyte antigen DR expression during the post-transplant period as well as during transplant-related adverse events of 30 pediatric patients and young adults with hemato-oncological malignancies and immunodeficiency disorders in comparison to healthy children and young adults. [Ann Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

ARIAD Announces Phase II Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015
ARIAD Pharmaceuticals, Inc. announced that it has concluded consultations with U.S. and European health authorities regarding the design of a randomized, dose-ranging trial to evaluate three starting doses of Iclusig^® in patients with refractory, chronic-phase chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc.]
Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

NEW Research Group Leader Position – Tissue Engineering (The Institute for Bioengineering of Catalonia)

Postdoctoral Position – Hematopoietic Gene Regulation and Leukemia (Boston Children’s Hospital)

Director of Bone Marrow Transplant (University of Utah)

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School at Houston)

Cord Tissue Processing Technician (Cord Blood Registry)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.